Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 2/20 | 0.33 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | ACE | P12821 | 1/20 | 0.31 |
| ▸ | CPT2 | P23786 | 1/20 | 0.31 |
| ▸ | CPT1A | P50416 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3930922 | 0.84 | CYP3A4 (0.41) | CYP3A4CYP2D6BCHEL3MBTL3ACE | |
| SCHEMBL15386556 | 0.84 | CYP3A4 (0.41) | CYP3A4CYP2D6BCHEL3MBTL3ACE | |
| SCHEMBL8260203 | 0.84 | CYP3A4 (0.41) | CYP3A4CYP2D6BCHEL3MBTL3ACE | |
| SCHEMBL8261848 | 0.78 | CYP3A4 (0.37) | CYP3A4CYP2D6BCHECPT2CPT1A | |
| SCHEMBL14434721 | 0.78 | CYP3A4 (0.37) | CYP3A4CYP2D6BCHECPT2CPT1A | |
| SCHEMBL20063360 | 0.78 | CYP3A4 (0.38) | CYP3A4CYP2D6BCHEL3MBTL3 | |
| SCHEMBL25663879 | 0.78 | CYP3A4 (0.38) | CYP3A4CYP2D6ACE | |
| SCHEMBL20063354 | 0.78 | CYP3A4 (0.38) | CYP3A4CYP2D6ACE | |
| SCHEMBL13876916 | 0.78 | CYP3A4 (0.38) | CYP3A4CYP2D6BCHEL3MBTL3CPT2 | |
| SCHEMBL14026513 | 0.78 | CYP3A4 (0.38) | CYP3A4CYP2D6BCHEL3MBTL3CPT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110306572-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER USING COX-2 INHIBITORS AND DUAL InHIBITORS OF EGFR [ErbB1] AND HER-2 [ErbB2] | TRAGARA PHARMACEUTICALS, INC (US) | 2011-12-15 | — | — | US | claimed |
| US-6828320-B2 | Enzyme inhibitors; anticancer agents | SMITHKLINE BEECHAM CORPORATION | 2004-12-07 | — | — | US | claimed |
| EP-0912570-B1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2003-09-10 | — | — | EP | claimed |
| EP-0912572-B1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2003-01-15 | — | — | EP | claimed |
| EP-0912559-B1 | FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2002-11-06 | — | — | EP | claimed |
| US-6391874-B1 | ANTICARCINOGENIC AGENTS; SKIN DISORDERS | SMITHKLINE BEECHAM CORPORATION | 2002-05-21 | — | — | US | claimed |
| US-6207669-B1 | IN TREATMENT OF CANCER AND PSORIASIS | GLAXO WELLCOME INC. | 2001-03-27 | — | — | US | claimed |
| US-6174889-B1 | PROTEIN TYROSINE KINASE INHIBITORS RELATED TO BIOISOSTERES OF QUINOLINE AND QUINAZOLINE DERIVATIVES; ANTICARCINOGENIC AND -TUMOR AGENTS; PSORIASIS; RESTENOSIS; RHEUMATOID ARTHRITIS, AUTOIMMUNE DISEASE, ALLERGY, ASTHMA AND GRAFT REJECTION | GLAXO WELLCOME INC. | 2001-01-16 | — | — | US | claimed |
| EP-0912559-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1999-05-06 | — | — | EP | claimed |
| EP-0912570-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1999-05-06 | — | — | EP | claimed |
| EP-0912572-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1999-05-06 | — | — | EP | claimed |
| WO-1998002438-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1998-01-22 | — | — | WO | claimed |
| WO-1998002437-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1998-01-22 | — | — | WO | claimed |
| WO-1998002434-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1998-01-22 | — | — | WO | claimed |
| US-20110306572-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER USING COX-2 INHIBITORS AND DUAL InHIBITORS OF EGFR [ErbB1] AND HER-2 [ErbB2] | TRAGARA PHARMACEUTICALS, INC (US) | 2011-12-15 | — | — | US | disclosed |
| US-20070161665-A1 | Cancer treatment method | SMITHKLINE BEECHAM CORPORATION | 2007-07-12 | — | — | US | disclosed |
| EP-1682123-A1 | CANCER TREATMENT METHOD | SmithKline Beecham (Cork) Limited (IE) | 2006-07-26 | — | — | EP | disclosed |
| WO-1998002438-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1998-01-22 | — | — | WO | disclosed |
| WO-1998002437-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1998-01-22 | — | — | WO | disclosed |
| WO-1998002434-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1998-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306572-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER USING COX-2 INHIBITORS AND DUAL InHIBITORS OF EGFR [ErbB1] AND HER-2 [ErbB2] | ERBB2, EGFR, ERBB3 | CYP3A4 3304/4885CYP2D6 1792/4885BCHE 4568/4885 |
| US-20070161665-A1 | Cancer treatment method | ERBB2, EGFR, PIK3CA | CYP3A4 3562/4885CYP2D6 3495/4885BCHE 2294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.